Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus sintilimab versus docetaxel alone as second-line treatment for driver-negative advanced non-small cell lung cancer
ChiCTR1900025548Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Apr 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of docetaxel and sintilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoints: disease control rate and objective response rate. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
docetaxelsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900025548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025548.